-
Do patients with chronic inflammatory skin disease affect the incidence of inflammatory bowel disease?
Time of Update: 2022-08-16
. Methods : In this cohort study, we used nationwide longitudinal commercial insurance claims data in the United States to identify adults and children who were seen by a dermatologist with a diagnosis of psoriasis, atopic Dermatitis, alopecia areata, vitiligo, or purulent dermatitis .
-
ARD: What is the success rate of discontinuation of glucocorticoids after initial therapy in RA patients?
Time of Update: 2022-08-16
. Methods : A systematic literature search was performed to identify observational cohorts and clinical trials of RA patients receiving initial GC bridging therapy (defined as discontinuation of GC therapy within 1 year) .
-
ARD: Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with more than 2000 patient-year exposures
Time of Update: 2022-08-16
Treatment-emergent adverse events (TEAEs , defined as events that first occurred or worsened in severity after baseline and on or before the last day of the treatment period ) and selected adverse events (AEs) were reported with every 100 The patient-year exposure-adjusted incidence rate (EAIR) was expressed .
-
ARD: IL-12/23 pathway inhibitors ustekinumab or TNFi have comparable persistence and efficacy in patients with psoriatic arthritis
Time of Update: 2022-08-16
Safety was similar in both groups Conclusions : In the real-world PsABio study, after 1 year of treatment, while unadjusted ustekinumab persistence was numerically slightly higher than TNFi , unadjusted efficacy was numerically slightly higher than TNFi ustekinumab , but a propensity-score-adjusted comparison showed comparable overall persistence, efficacy, and safety for ustekinumab and TNFi for both modes of action in PsA .
-
Learn to judge the signs of bone damage and kill "necrosis" in the cradle!
Time of Update: 2022-08-16
. Currently, disease activity measured by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score is considered to be the main risk factor for osteonecrosis in early SLE .
-
How should rheumatoid patients choose biologics?
Time of Update: 2022-08-16
After receiving adalimumab treatment to meet the standard, the disease recurrence rate within 1 year of drug withdrawal is low, and it can significantly and long-term improve the symptoms and signs of all kinds of RA patients, and improve the quality of life of patients .
-
Rheumatol Ther: Long-Term Study of Secukinumab in Patients with Psoriatic Arthritis or Ankylosing Spondylitis
Time of Update: 2022-08-16
Both PsA and AS are interrelated disorders with various common clinical, genetic, and immune featuresPsoriatic arthritis presents with variability in disease activity and clinical presentation, and is characterized by articular and extra-articular manifestations, including peripheral arthritis, axial involvement, tendinitis, dactylitis, and skin or nail disease .
-
ARD: Development and Initial Validation of the Sjogren's Response Assessment Tool (STAR): A Consensus Composite Score for Evaluating Treatment Effects in Primary Sjögren's Syndrome
Time of Update: 2022-08-16
Method :methodTo develop STAR , the NECESSITY (New Clinical Endpoint in Primary Sjögren's Syndrome: Interventional Trial Based on Patient Stratification) consortium used a data-driven approach based on nine randomised controlled trials (RCTs) and involving 78 specialists and 20 patients consensus technology .
-
Case sharing: What should I do if I encounter atypical gout?
Time of Update: 2022-08-16
Chen Jian Attending Physician, Master of Medicine Introduction: Attending physician in the Department of Rheumatology and Immunology, The Third Affiliated Hospital of Guangzhou Medical University, graduated from Guangdong Provincial People's Hospital of Southern Medical University with a master's degree .
-
ARD: Tocilizumab in New-Onset Polymyalgia Rheumatica (PMR-SPARE): A Phase 2/3 Randomized Controlled Trial
Time of Update: 2022-08-16
Conclusions In patients with new-onset polymyalgia rheumatica who received rapid glucocorticoid tapering, tocilizumab was superior to placebo for sustained glucocorticoid-free remission, time to relapse, and cumulative glucocorticoid dose .
-
ARD: Antibody titers after vaccination predict protection against COVID-19 in patients with autoimmune disease: a survival analysis in a prospective cohort
Time of Update: 2022-08-16
OBJECTIVE : To assess the incidence and risk factors of breakthrough COVID-19 infection in a cohort of vaccinated patients with autoimmune rheumatic diseases (AIRDs) and to determine whether antibodies against the receptor-binding domain (anti-RBD) of the spike protein as a reliable predictor of susceptibility to such infections .
-
A&R: Efficacy of a short-term bridging strategy with different doses of prednisolone on imaging and clinical outcomes in active early rheumatoid arthritis
Time of Update: 2022-08-16
. Methods: Adult RA patients with moderate / high disease activity from one rheumatology hospital and 23 rheumatology treatment centers were randomized (1:1:1) to 60 mg (high dose, HDP ) and 10 mg daily Prednisolone (low dose, LDP , tapering to 0 mg over 12 weeks ) or placebo .
-
ADV: A Study of Methotrexate Efficacy, Adverse Events and Folic Acid Regimen in Pediatric Patients with Plaque Psoriasis
Time of Update: 2022-08-16
Acta Derm Venereol 2022 May 23;Source: Bruins F, Van Acht M, Bronckers I, Real-world Methotrexate Use in a Prospective Cohort of Paediatric Patients with Plaque Psoriasis: Effectiveness, Adverse Events and Folic Acid Regimen.
-
6 kinds of Chinese patent medicines commonly used in rheumatoid, you must know!
Time of Update: 2022-08-16
Indication syndrome: Tongbiling tablet mainly treats rheumatism invasion syndrome, rheumatism invasion type is mostly swelling and pain of muscles, bones and joints, but there is no local cold and heat, abnormal skin color, and no preference for warmth Or intolerance to cold, pale red tongue, greasy coating, and tight pulse are the main clinical features .
-
Two or three things about scleroderma: "disfigured" disease, "loving" women, what to do?
Time of Update: 2022-08-16
How does TCM treat scleroderma?Traditional Chinese medicine believes that the cause of "pigmentation" is due to the invasion of exogenous wind, cold and dampness pathogens, and the internal cause of deficiency of spleen and kidney yang, and the disharmony of qi and blood .
-
Edamame is paired with wine, gout often occurs!
Time of Update: 2022-08-16
Eating "beans" is important for goutEating "beans" is important for goutAlthough the purine content of soy products is not high, eating right can not only supplement nutrition, but also not increase uric acid .
-
ARD: EULAR points to consider when analyzing and reporting comparative effectiveness studies using observational data in rheumatology
Time of Update: 2022-08-16
, et al Annals of the Rheumatic Diseases 81: Leave a message here OBJECTIVE : Comparing treatment effects in observational settings over time is hindered by several major factors, including confounding and dropout bias .
-
Heidelb: A study of tuberculosis-positive conversion rates in patients with psoriasis treated with adalimus and scuqiyu
Time of Update: 2022-08-16
Dermatol Ther (Heidelb) 2022 May 26;Source: Xiao Y, Chen H, Zou Q The Tuberculosis Positive Conversion Rate Among Psoriasis Patients Treated with Adalimumab and Secukinumab: A Single-Center Retrospective Study in China.
-
Arthritis Res Ther: Targeted therapy is safe and effective for elderly patients with rheumatoid arthritis
Time of Update: 2022-08-16
. In recent years, with the improvement of life prognosis in elderly patients with rheumatoid arthritis (RA), the increase in the incidence of elderly-onset RA, and the increased cumulative risk of RA in elderly women, the number of elderly RA patients has increased .
-
JEADV: 1-year effect study of Guselkumab in the treatment of psoriasis
Time of Update: 2022-08-16
J Eur Acad Dermatol Venereol 2022 May 15Source: Gerdes S, Asadullah K, Hoffmann M, Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.